Xu Kexin, Tam Po-Chor, Hou Shukun, Wang Xiaofeng, Bai Wenjun
Department of Urology, People's Hospital, Peking University, Beijing 100044, China.
Chin Med J (Engl). 2002 Nov;115(11):1736-8.
To investigate a non-invasive, effective and rapid mode of detecting the recurrence of bladder cancer during follow-up.
Ninety patients following transurethral resection of bladder tumor (TURBt) surgery were recruited from January 1998 to March 2000. Standard ELISA was used to determine the quantity of nuclear matrix protein (NMP-22) in urine of all bladder cancer patients during their follow-up periods. Urine bladder tumor antigen (BTA) stat test was simultaneously performed and followed by cystoscopy.
The total positive rates of urinary NMP-22 and BTA stat test were 76.7% (33/43) and 67.4% (29/43), respectively. Comparatively, this positive rate would increase to 93.0% (40/43) when the combination of both urine NMP-22 and BTA test were adopted.
Examination of NMP-22 in urine is a rapid and effective way to detect the recurrence of bladder cancer. If combined with BTA test, NMP-22 may be used as a non-invasive method in surveillance of recurring of bladder cancer, which may reduce the frequency of patients needing to undergo conventional invasive cystoscopy.
研究一种在随访期间检测膀胱癌复发的无创、有效且快速的方法。
选取1998年1月至2000年3月期间行经尿道膀胱肿瘤切除术（TURBt）的90例患者。采用标准酶联免疫吸附测定法（ELISA）测定所有膀胱癌患者随访期间尿液中核基质蛋白（NMP-22）的含量。同时进行尿膀胱肿瘤抗原（BTA）stat检测，随后进行膀胱镜检查。
尿NMP-22和BTA stat检测的总阳性率分别为76.7%（33/43）和67.4%（29/43）。相比之下，当同时采用尿NMP-22和BTA检测时，阳性率将增至93.0%（40/43）。
检测尿液中的NMP-22是检测膀胱癌复发的一种快速有效的方法。若与BTA检测相结合，NMP-22可作为一种无创方法用于监测膀胱癌复发，这可能会减少患者接受传统侵入性膀胱镜检查的频次。
